Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥487.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.65B

Enterprise Value¥3.38K

Total Cash (Recent Filing)¥3.53B

Total Debt (Recent Filing)¥1.24B

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-89.44

Shares Outstanding10,092,100

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Regenova Bioprinting PlatformCyfuse's core Regenova 3D cell assembly technology represents a durable, specialized asset in regenerative medicine and research tools. Owning a differentiated platform supports recurring consumable sales, service revenue and partnership leverage, sustaining long-term demand as biotech R&D and cell therapy development expand.

Material Revenue Recovery And GrowthA substantial 2025 revenue rebound and positive gross margin indicate renewed commercial traction for its platform and services. This topline recovery suggests growing customer adoption and potential to scale unit economics over time if the company converts demand into repeat consumables, services, and collaborations.

Manageable Leverage And Sizable Equity BaseDebt-to-equity near 0.48 and a sizable equity/asset base provide financial flexibility versus highly leveraged peers. Manageable leverage helps preserve runway for further R&D and commercialization, enabling the firm to fund operations or strategic partnerships while it works to convert revenue growth into positive cash flow.

Bears Say

Persistent Negative Cash GenerationConsistent and deep negative operating and free cash flow indicate the business cannot self-fund operations and relies on external capital. Even with revenue recovery, ongoing cash burn raises execution and financing risk, constraining the company’s ability to invest in scale-up without dilutive or costly funding.

Severe Operating And Net LossesExtremely negative EBIT and net margins show the cost structure is not yet scalable versus revenue. Persistent large losses erode equity over time, hinder reinvestment capacity, and require either significant margin improvement or continued external funding to sustain long-term commercialization and R&D efforts.

Very Small Headcount Limits ScalingA team of 23 employees constrains commercial reach, customer support, and product development capacity for a hardware-plus-consumables platform. Limited internal resources increase reliance on partners or outsourcing, slowing adoption and risking execution delays as demand and product complexity grow.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥487.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.65B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Nov 12, 2026 which is in 87 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Aug 14, 2026. The company reported -¥20.905 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥20.905 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.633%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.